These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23907144)

  • 1. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.
    Kahana A; Worden FP; Elner VM
    JAMA Ophthalmol; 2013 Oct; 131(10):1364-6. PubMed ID: 23907144
    [No Abstract]   [Full Text] [Related]  

  • 2. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 6. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 7. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 8. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 9. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 10. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
    Kaehler KC; Gutzmer R; Egberts F; Hauschild A
    J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
    [No Abstract]   [Full Text] [Related]  

  • 11. Histologic changes in basal cell carcinoma after treatment with vismodegib.
    Aldabagh B; Yu J; Perkocha LA; Arron S
    Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864
    [No Abstract]   [Full Text] [Related]  

  • 12. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma].
    Wolodarski M; Lapins J; Hansson J
    Lakartidningen; 2013 Apr 24-May 6; 110(17-18):886-8. PubMed ID: 23717940
    [No Abstract]   [Full Text] [Related]  

  • 14. Vismodegib.
    Dlugosz A; Agrawal S; Kirkpatrick P
    Nat Rev Drug Discov; 2012 Jun; 11(6):437-8. PubMed ID: 22653209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
    Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
    J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
    Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
    N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 19. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.